Skip to content

Study · In vitro (cells) · 2022

3 results

Developmental endothelial locus-1 attenuates palmitate-induced apoptosis in tenocytes through the AMPK/autophagy-mediated suppression of inflammation and endoplasmic reticulum stress.

Park TJ, Park SY, Cho W, Oh H, Lee HJ, Abd El-Aty AM, Bayram C, Jeong JH, Jung TW

Bone & joint research1 Dec 2022Cited by 10 (Europe PMC)

PMID36458454 (opens in a new tab)PMCIDPMC9792873 (opens in a new tab)DOI10.1302/2046-3758.1112.bjr-2022-0077.r2 (opens in a new tab)PepBankPUB-36458454
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In human primary tenocytes, AICAR attenuated palmitate-induced inflammation, and 3-MA reversed this effect.

    In plain wordsIn cells, AICAR reduced inflammation from palmitate compared with palmitate alone, and an autophagy inhibitor reversed this effect.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseInflammation
    Study

    humann: not reported in source

    primary tenocytes exposed to palmitate
    Comparator
    palmitate exposure without AICAR
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similar to DEL-1, 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), an activator of AMPK, also attenuated palmitate-induced inflammation, ER stress, and apoptosis in tenocytes, which 3-MA reversed.
    1 context sentence
    Summary · context
    Human primary tenocytes were cultured in palmitate (400 μM) and palmitate plus DEL-1 (0 to 2 μg/ml) conditions for 24 hours.
  2. 02LabIn vitro (cells)Mechanism

    In human primary tenocytes, AICAR attenuated palmitate-induced ER stress, and 3-MA reversed this effect.

    In plain wordsIn cells, AICAR reduced stress from palmitate compared with palmitate alone, and an autophagy inhibitor reversed this effect.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseEndoplasmic reticulum stress
    Study

    humann: not reported in source

    primary tenocytes exposed to palmitate
    Comparator
    palmitate exposure without AICAR
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similar to DEL-1, 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), an activator of AMPK, also attenuated palmitate-induced inflammation, ER stress, and apoptosis in tenocytes, which 3-MA reversed.
    1 context sentence
    Summary · context
    Human primary tenocytes were cultured in palmitate (400 μM) and palmitate plus DEL-1 (0 to 2 μg/ml) conditions for 24 hours.
  3. 03LabIn vitro (cells)Mechanism

    In human primary tenocytes, AICAR attenuated palmitate-induced apoptosis, and 3-MA reversed this effect.

    In plain wordsIn cells, AICAR reduced cell death from palmitate compared with palmitate alone, and an autophagy inhibitor reversed this effect.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseApoptosis
    Study

    humann: not reported in source

    primary tenocytes exposed to palmitate
    Comparator
    palmitate exposure without AICAR
    Outcome group
    Tendon and ligament healing · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similar to DEL-1, 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), an activator of AMPK, also attenuated palmitate-induced inflammation, ER stress, and apoptosis in tenocytes, which 3-MA reversed.
    1 context sentence
    Summary · context
    Human primary tenocytes were cultured in palmitate (400 μM) and palmitate plus DEL-1 (0 to 2 μg/ml) conditions for 24 hours.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.